FibroBiologics Announces Anticipated Listing Day

HOUSTON, Jan. 25, 2024 /PRNewswire/ — FibroBiologics, Inc. (“FibroBiologics”), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has been notified by NASDAQ that trading of its common stock will commence on Wednesday, January 31, 2024.

FibroBiologics to Present at Biotech Showcase 2024

HOUSTON, January 4, 2023 – FibroBiologics, Inc., a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will attend the Biotech Showcase in San Francisco, CA from January 8-10, 2024. Biotech Showcase is a premier event for private and mid-cap biotechnology companies to highlight their innovation by connecting with global investors and engaging with executives from prominent biopharmaceutical interests.

FibroBiologics to Host Investor Day

HOUSTON, December 7, 2023 – FibroBiologics, Inc., a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it will hold an Investor Day on December 14, 2023, at 10 a.m. EST. A live webcast will be accessible here as well as […]